These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35713302)

  • 1. Single-center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression.
    Mecadon K; Arvanitis P; Farmakiotis D; Rogers R
    Clin Transplant; 2022 Aug; 36(8):e14752. PubMed ID: 35713302
    [No Abstract]   [Full Text] [Related]  

  • 2. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
    Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
    Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Nirmatrelvir/Ritonavir and Tacrolimus in a Kidney Transplant Recipient With COVID-19.
    Lindauer KE; Hamel AG
    Am Fam Physician; 2022 Jun; 105(6):569-570. PubMed ID: 35704835
    [No Abstract]   [Full Text] [Related]  

  • 5. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.
    Salerno DM; Jennings DL; Lange NW; Kovac DB; Shertel T; Chen JK; Hedvat J; Scheffert J; Brown RS; Pereira MR
    Am J Transplant; 2022 Aug; 22(8):2083-2088. PubMed ID: 35278260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
    Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
    Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
    Solomon S; Colovai A; Del Rio M; Hayde N
    Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ; Yang HC; Holman MJ; Ahsan N
    J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
    Noble J; Jouve T; Rostaing L; Malvezzi P
    Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
    Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
    Guzmán Cordero C; Saez-Torres de Vicente M
    Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
    Tsai SF; Cheng CY; Shu KH; Wu MJ
    Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower versus higher starting tacrolimus dosing in kidney transplant recipients.
    Chua JCM; Mount PF; Lee D
    Clin Transplant; 2022 Jun; 36(6):e14606. PubMed ID: 35137970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
    Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
    [No Abstract]   [Full Text] [Related]  

  • 19. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
    Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients.
    Rummo O; Carmellini M; Kamar N; Durrbach A; Mousson C; Caputo F; Mathe Z; Christiaans MHL; Kuypers DRJ; Klempnauer J; Anaokar S; Hurst M; Kazeem G; Undre N; Lehner F
    Transpl Int; 2020 Feb; 33(2):161-173. PubMed ID: 31536654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.